Aktuelle Dermatologie 2011; 37(6): 199-204
DOI: 10.1055/s-0030-1256328
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Diagnostik primär kutaner B-Zell-Lymphome

Diagnostic Criteria of Primary Cutaneous B-Cell LymphomasM.  Felcht1 , C.-D.  Klemke1
  • 1Klinik für Dermatologie, Venerologie and Allergologie, Universitätsklinikum Mannheim, Ruprecht-Karls-Universität Heidelberg
Further Information

Publication History

Publication Date:
18 April 2011 (online)

Zusammenfassung

Primär kutane B-Zell-Lymphome (PCBCL) sind seltene Erkankungen der Haut. Die drei wichtigsten Subtypen sind die indolent verlaufenden primär kutanen follikulären Lymphome (PCFCL) und die primär kutanen Marginalzonenlymphome (PCMZL) sowie das deutlich aggressiver verlaufende primär kutane diffus großzellige B-Zell-Lymphom des Beines (PCLBCL, LT). Bei der Verdachtsdiagnose PCBCL muss zunächst ein nodales Lymphom mit sekundärer Hautbeteiligung durch entsprechende Staginguntersuchungen ausgeschlossen werden. Die Differenzierung zwischen den einzelnen Subtypen ist in den meisten Fällen mittels Anamnese, Klinik und (Immun)-Histologie möglich. In Einzelfällen erscheinen molekular-biologische Untersuchungen gerechtfertigt.

Abstract

Primary cutaneous B-cell lymphomas (PCBL) are rare skin tumors. The three major subtypes are the indolent variants primary cutaneous follicle centre lymphoma (PCFCL) and primary cutaneous marginal zone lymphoma (PCMZL), and the more aggressive PCBCL primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT). After a nodal lymphoma with secondary skin involvement has been excluded by staging procedures, the differentiation between the subtypes is in most cases possible by the medical history, clinical examination and (immuno)-histochemical analysis. However, in some cases molecular analyses are required to achieve diagnosis.

Literatur

  • 1 Turner J J, Morton L M, Linet M S et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions.  Blood. 2010;  116 (20) in press
  • 2 Groves F D, Linet M S, Travis L B, Devesa S S. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995.  J Natl Cancer Inst. 1995;  92 (15) 1240-1251
  • 3 Bradford P T, Devesa S S, Anderson W F, Toro J R. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.  Blood. 2009;  113 (21) 5064-5073
  • 4 Jenni D, Karpova M B, Seifert B et al. Primary cutaneous lymphoma: Two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre.  Br J Dermatol. 2010 Nov 16;  [Epub ahead of print]
  • 5 Willemze R, Jaffe E S, Burg G et al. WHO-EORTC classification of cutaneous lymphomas.  Blood. 2005;  105 3768-3785
  • 6 Senff N J, Noordijk E M, Kim Y H et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommandations for the management of cutaneous B-cell lymphomas.  Blood. 2008;  112 (5) 1600-1609
  • 7 Stadler R, Assaf C, Klemke C-D et al. Short German guidelines: Cutaneous lymphomas.  J Deut Dermatol Ges. 2008;  6 S25-S31
  • 8 Ponzoni M, Ferreri A JM, Campo E et al. Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting.  J Clin Oncol. 2007;  25 (21) 3168-3173
  • 9 Kim F Y, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas others than mycosis fungoides and Sézary Syndrom: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treamtent of Cancer (EORTC).  Blood. 2007;  110 479-484
  • 10 Senff N J, Hoefnagel J, Neelis K et al. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.  Arch Dermatol. 2007;  143 (12) 1520-1526
  • 11 Senff N J, Hoefnagel J J, Jansen P M et al. Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO-EORTC Classification for Cutaneous Lymphomas: Complarison With Previous Classifications and Identification of Prognostic Markers.  J Clin Oncol. 2007;  25 1581-1587
  • 12 Senff N J, Willemze R. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used in the Dutch Cutaneous Lymphoma Group.  Br J Dermatol. 2007;  157 (6) 1205-1211
  • 13 Gerami P, Wickless S C, Rosen S et al. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.  J Am Acad Dermatol. 2008;  59 (2) 245-254
  • 14 Zinzani P L, Quaglino P, Pimpinelli N et al. Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas.  J Clin Oncol. 2006;  24 (9) 1376-1382
  • 15 Assaf C, Gellrich S, Steinhoff M et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG).  J Deut Dermatol Ges. 2007;  5 662-669
  • 16 Willemze R. Primary cutaneous B-cell lymphoma: classification and treatment.  Curr Opin Oncol. 2006;  18 425-431
  • 17 Senff N J, Kluin-Nelemans H C, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphomas.  Br J Haematol. 2008;  142 52-56
  • 18 Hoefnagel J J, Vemeer M H, Jansen P et al. Primary Cutaneous Marginal Zone B-Cell Lymphoma.  Arch Dermatol. 2005;  141 1139-1145
  • 19 Garbea A, Dippel E, Hildenbrand R et al. Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer.  Br J Dermatol. 2002;  146 144-147
  • 20 Nakayama S, Yokote T, Kobayashi K et al. Primary cutaneous diffuse large B-cell lymphoma, leg type, with features simulating POEMS syndrome.  Eur J Haematol. 2010;  84 (1) 79-83
  • 21 Burg G, Kempf W, Cozzio A et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects.  J Cutan Pathol. 2005;  32 647-674
  • 22 Cerroni L, Volkenandt M, Rieger E et al. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas.  The Journal of investigative dermatology. 1994;  102 (2) 231-235
  • 23 Hoefnagel J J, Vermeer M H, Jansen P M et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance.  Br J Dermatol. 2003;  149 1183-1191
  • 24 Kodama K, Massone C, Chott A et al. Primary cutaneous large B-cell lymphomas: clinicopathological features, classification, and prognostic factors in a large series of patients.  Blood. 2005;  106 2491-2497
  • 25 Hoefnagel J J, Dijkman R, Basso K et al. Dinstinct types of primary cutaneous large B-cell lymphoma identified by gene expressing profiling.  Blood. 2005;  105 3671-3678
  • 26 Paulli M, Viglio A, Vivenza D et al. Primary Cutaneous Large B-Cell Lymphoma of the Leg: Histogenetic Analysis of a Controversial Clinicopathologic Entity.  Hum Path. 2002;  33 (9) 937-943
  • 27 Sandberg Y, van Gastel-Mol E J, Verhaaf B et al. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace southern blot analysis in routine clonality diagnostics.  J Mol Diagn. 2005;  7 495-503
  • 28 Klemke C D, Dippel E, Dembinski A et al. Clonal T cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in the skin and blood of patients with parapsoriasis and early-stage mycosis fungoides.  J Pathol. 2002;  197 (3) 348-354
  • 29 McClure R F, Kaur P, Pagel E et al. Validation of immunoglobulin gene rearrangements detection by PCR using commerically available BIOMED-2 primer.  Leukemia. 2006;  20 176-179
  • 30 Klemke C D, Fritzsching B, Franz B et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas.  Leukemia. 2006;  20 (6) 1123-1129
  • 31 Evans P, Pott C, Groenen P et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936.  Leukemia. 2007;  21 207-214
  • 32 Morales A V, Arber D A, Seo K et al. Evaluation of B-Cell Clonality Using the BIOMED-2 PCR Method Effectively Distinguishes Cutaneous B-Cell Lymphoma From Beningn Lymphoid Malignancies.  Am J Dermatopathol. 2008;  30 425-430
  • 33 Felcht M, Booken N, Stroebel P et al. The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinic, histology and immunohistochemistry.  J Am Acad Dermatol. 2011;  64 (1) 135-143
  • 34 Dippel E, Assaf C, Hummel M et al. Clonal T-Cell receptor gamma-chain gene rearrangment by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: a critical evaluation.  J Pathol. 1999;  188 (2) 146-154
  • 35 Dippel E, Klemke C-D, Hummel M et al. T-cell clonality of undetermined significance.  Blood. 2001;  98 (1) 247-248
  • 36 Klemke C-D, Poenitz N, Dippel E et al. T-Cell Clonality of Undetermined Significance.  Arch Dermatol. 2006;  142 393-394

PD Dr. med. Claus-Detlev Klemke MD 

Klinik für Dermatologie, Venerologie und Allergologie
Universitätsklinikum Mannheim
Ruprecht-Karls-Universität Heidelberg

Theodor-Kutzer-Ufer 1 – 3
68135 Mannheim

Email: Claus-Detlev.Klemke@umm.de

    >